APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pancreatic Endocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pancreatic Endocrine Tumor Drug Market Outlook and Growth Opportunities 2026

26 December 2025196 pages

Choose your research edition.

Industry ResearchPancreatic Endocrine Tumor Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Pancreatic Endocrine Tumor Drug Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Pancreatic Endocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pancreatic Endocrine Tumor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pancreatic Endocrine Tumor Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pancreatic Endocrine Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pancreatic Endocrine Tumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pancreatic Endocrine Tumor Drug market include Ipsen S.A., MediaPharma s.r.l., OXiGENE, Inc., Jiangsu Hengrui Medicine Co., Ltd. and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pancreatic Endocrine Tumor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pancreatic Endocrine Tumor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pancreatic Endocrine Tumor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pancreatic Endocrine Tumor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pancreatic Endocrine Tumor Drug Segment by Company

Ipsen S.A.

MediaPharma s.r.l.

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Pancreatic Endocrine Tumor Drug Segment by Type

Buparlisib Hydrochloride

Dovitinib Lactate

Fosbretabulin Tromethamine

Lanreotide Acetate

MPHE-001B

Others

Pancreatic Endocrine Tumor Drug Segment by Application

Clinic

Research Center

Hospital

Pancreatic Endocrine Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pancreatic Endocrine Tumor Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pancreatic Endocrine Tumor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pancreatic Endocrine Tumor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Pancreatic Endocrine Tumor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pancreatic Endocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pancreatic Endocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pancreatic Endocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pancreatic Endocrine Tumor Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pancreatic Endocrine Tumor Drug industry.

Chapter 3: Detailed analysis of Pancreatic Endocrine Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pancreatic Endocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pancreatic Endocrine Tumor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pancreatic Endocrine Tumor Drug Industry Trends Table 2. Pancreatic Endocrine Tumor Drug Industry Drivers Table 3. Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges Table 4. Pancreatic Endocrine Tumor Drug Industry Restraints Table 5. Global Pancreatic Endocrine Tumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pancreatic Endocrine Tumor Drug Revenue Share by Company (2021-2026) Table 7. Global Pancreatic Endocrine Tumor Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Company (2021-2026) Table 9. Global Pancreatic Endocrine Tumor Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pancreatic Endocrine Tumor Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pancreatic Endocrine Tumor Drug Key Company Manufacturing Base & Headquarters Table 12. Global Pancreatic Endocrine Tumor Drug Company, Product Type & Application Table 13. Global Pancreatic Endocrine Tumor Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pancreatic Endocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Buparlisib Hydrochloride Table 18. Significant Companies of Dovitinib Lactate Table 19. Significant Companies of Fosbretabulin Tromethamine Table 20. Significant Companies of Lanreotide Acetate Table 21. Significant Companies of MPHE-001B Table 22. Significant Companies of Others Table 23. Global Pancreatic Endocrine Tumor Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Pancreatic Endocrine Tumor Drug Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Pancreatic Endocrine Tumor Drug Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Type (2021-2026) Table 27. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Type (2027-2032) Table 28. Global Pancreatic Endocrine Tumor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pancreatic Endocrine Tumor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Pancreatic Endocrine Tumor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Type (2021-2026) Table 32. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Research Center Table 35. Significant Companies of Hospital Table 36. Global Pancreatic Endocrine Tumor Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Pancreatic Endocrine Tumor Drug Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Pancreatic Endocrine Tumor Drug Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Application (2021-2026) Table 40. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Application (2027-2032) Table 41. Global Pancreatic Endocrine Tumor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Pancreatic Endocrine Tumor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Pancreatic Endocrine Tumor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Application (2021-2026) Table 45. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Application (2027-2032) Table 46. Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Pancreatic Endocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 48. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2021-2026) Table 49. Global Pancreatic Endocrine Tumor Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2027-2032) Table 51. Global Pancreatic Endocrine Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Pancreatic Endocrine Tumor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Region (2021-2026) Table 54. Global Pancreatic Endocrine Tumor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Region (2027-2032) Table 56. Global Pancreatic Endocrine Tumor Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Pancreatic Endocrine Tumor Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Pancreatic Endocrine Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 61. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 62. Global Pancreatic Endocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 63. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2027-2032) Table 64. Global Pancreatic Endocrine Tumor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Pancreatic Endocrine Tumor Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Pancreatic Endocrine Tumor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Pancreatic Endocrine Tumor Drug Sales Value Market Share by Country (2027-2032) Table 68. Ipsen S.A. Company Information Table 69. Ipsen S.A. Business Overview Table 70. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio Table 72. Ipsen S.A. Recent Development Table 73. MediaPharma s.r.l. Company Information Table 74. MediaPharma s.r.l. Business Overview Table 75. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio Table 77. MediaPharma s.r.l. Recent Development Table 78. OXiGENE, Inc. Company Information Table 79. OXiGENE, Inc. Business Overview Table 80. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio Table 82. OXiGENE, Inc. Recent Development Table 83. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 84. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 85. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio Table 87. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 88. Novartis AG Company Information Table 89. Novartis AG Business Overview Table 90. Novartis AG Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio Table 92. Novartis AG Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Pancreatic Endocrine Tumor Drug Distributors List Table 96. Pancreatic Endocrine Tumor Drug Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Pancreatic Endocrine Tumor Drug Product Image Figure 2. Global Pancreatic Endocrine Tumor Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pancreatic Endocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pancreatic Endocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 5. Global Pancreatic Endocrine Tumor Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pancreatic Endocrine Tumor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Buparlisib Hydrochloride Image Figure 10. Dovitinib Lactate Image Figure 11. Fosbretabulin Tromethamine Image Figure 12. Lanreotide Acetate Image Figure 13. MPHE-001B Image Figure 14. Others Image Figure 15. Global Pancreatic Endocrine Tumor Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Pancreatic Endocrine Tumor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Pancreatic Endocrine Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pancreatic Endocrine Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Research Center Image Figure 23. Hospital Image Figure 24. Global Pancreatic Endocrine Tumor Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Pancreatic Endocrine Tumor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Pancreatic Endocrine Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Pancreatic Endocrine Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Application (2021-2032) Figure 30. Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Pancreatic Endocrine Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Pancreatic Endocrine Tumor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Pancreatic Endocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Pancreatic Endocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Pancreatic Endocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Pancreatic Endocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Pancreatic Endocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Pancreatic Endocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Pancreatic Endocrine Tumor Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Pancreatic Endocrine Tumor Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Buparlisib Hydrochloride
  • Dovitinib Lactate
  • Fosbretabulin Tromethamine
  • Lanreotide Acetate
  • MPHE-001B
  • Others
Applications
  • Clinic
  • Research Center
  • Hospital
Companies covered
  • Ipsen S.A.
  • MediaPharma s.r.l.
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pancreatic Endocrine Tumor Drug Sales Value (2021-2032)
  4. 1.2.2 Global Pancreatic Endocrine Tumor Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Pancreatic Endocrine Tumor Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pancreatic Endocrine Tumor Drug Market Dynamics
  1. 2.1 Pancreatic Endocrine Tumor Drug Industry Trends
  2. 2.2 Pancreatic Endocrine Tumor Drug Industry Drivers
  3. 2.3 Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Pancreatic Endocrine Tumor Drug Industry Restraints
3 Pancreatic Endocrine Tumor Drug Market by Company
  1. 3.1 Global Pancreatic Endocrine Tumor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Pancreatic Endocrine Tumor Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Pancreatic Endocrine Tumor Drug Average Price by Company (2021-2026)
  5. 3.5 Global Pancreatic Endocrine Tumor Drug Company Ranking (2024-2026)
  6. 3.6 Global Pancreatic Endocrine Tumor Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Pancreatic Endocrine Tumor Drug Company Product Type and Application
  8. 3.8 Global Pancreatic Endocrine Tumor Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pancreatic Endocrine Tumor Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pancreatic Endocrine Tumor Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pancreatic Endocrine Tumor Drug Market by Type
  1. 4.1 Pancreatic Endocrine Tumor Drug Type Introduction
  2. 4.1.1 Buparlisib Hydrochloride
  3. 4.1.2 Dovitinib Lactate
  4. 4.1.3 Fosbretabulin Tromethamine
  5. 4.1.4 Lanreotide Acetate
  6. 4.1.5 MPHE-001B
  7. 4.1.6 Others
  8. 4.2 Global Pancreatic Endocrine Tumor Drug Sales Volume by Type
  9. 4.2.1 Global Pancreatic Endocrine Tumor Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Pancreatic Endocrine Tumor Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Pancreatic Endocrine Tumor Drug Sales Value by Type
  13. 4.3.1 Global Pancreatic Endocrine Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Pancreatic Endocrine Tumor Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Pancreatic Endocrine Tumor Drug Sales Value Share by Type (2021-2032)
5 Pancreatic Endocrine Tumor Drug Market by Application
  1. 5.1 Pancreatic Endocrine Tumor Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Research Center
  4. 5.1.3 Hospital
  5. 5.2 Global Pancreatic Endocrine Tumor Drug Sales Volume by Application
  6. 5.2.1 Global Pancreatic Endocrine Tumor Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pancreatic Endocrine Tumor Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pancreatic Endocrine Tumor Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pancreatic Endocrine Tumor Drug Sales Value by Application
  10. 5.3.1 Global Pancreatic Endocrine Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pancreatic Endocrine Tumor Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pancreatic Endocrine Tumor Drug Sales Value Share by Application (2021-2032)
6 Pancreatic Endocrine Tumor Drug Regional Sales and Value Analysis
  1. 6.1 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pancreatic Endocrine Tumor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Pancreatic Endocrine Tumor Drug Sales by Region (2027-2032)
  5. 6.3 Global Pancreatic Endocrine Tumor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pancreatic Endocrine Tumor Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pancreatic Endocrine Tumor Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pancreatic Endocrine Tumor Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Pancreatic Endocrine Tumor Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pancreatic Endocrine Tumor Drug Sales Value (2021-2032)
  12. 6.6.2 North America Pancreatic Endocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pancreatic Endocrine Tumor Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Pancreatic Endocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pancreatic Endocrine Tumor Drug Sales Value (2021-2032)
  21. 6.9.2 South America Pancreatic Endocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pancreatic Endocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
7 Pancreatic Endocrine Tumor Drug Country-level Sales and Value Analysis
  1. 7.1 Global Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pancreatic Endocrine Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pancreatic Endocrine Tumor Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Pancreatic Endocrine Tumor Drug Sales by Country (2027-2032)
  6. 7.4 Global Pancreatic Endocrine Tumor Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pancreatic Endocrine Tumor Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pancreatic Endocrine Tumor Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pancreatic Endocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pancreatic Endocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pancreatic Endocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ipsen S.A.
  2. 8.1.1 Ipsen S.A. Company Information
  3. 8.1.2 Ipsen S.A. Business Overview
  4. 8.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio
  6. 8.1.5 Ipsen S.A. Recent Developments
  7. 8.2 MediaPharma s.r.l.
  8. 8.2.1 MediaPharma s.r.l. Company Information
  9. 8.2.2 MediaPharma s.r.l. Business Overview
  10. 8.2.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio
  12. 8.2.5 MediaPharma s.r.l. Recent Developments
  13. 8.3 OXiGENE, Inc.
  14. 8.3.1 OXiGENE, Inc. Company Information
  15. 8.3.2 OXiGENE, Inc. Business Overview
  16. 8.3.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio
  18. 8.3.5 OXiGENE, Inc. Recent Developments
  19. 8.4 Jiangsu Hengrui Medicine Co., Ltd.
  20. 8.4.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  21. 8.4.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  22. 8.4.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio
  24. 8.4.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pancreatic Endocrine Tumor Drug Value Chain Analysis
  2. 9.1.1 Pancreatic Endocrine Tumor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pancreatic Endocrine Tumor Drug Sales Mode & Process
  6. 9.2 Pancreatic Endocrine Tumor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pancreatic Endocrine Tumor Drug Distributors
  9. 9.2.3 Pancreatic Endocrine Tumor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst